Drugs / ARRY-382
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01316822 | Mar 2011 → Oct 2012 | metastatic malignant neoplasm | Array BioPharma | Completed | No outcome recorded |
| Phase 1/21 trial · 1 met primary | ||||||
| Phase 1/2 | NCT02880371 | Sep 2016 → Sep 2019 | cancer | Pfizer | Terminated | Met primary |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ARRY-382 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02880371 ↗ |
| Known as | PF-07265804 | “PURPOSE: ARRY-382 (PF-07265804) is a selective inhibitor of colony-stimulating factor-1 receptor.” PMID 35302585 ↗ Jun 2022 |
| Action | Inhibit | “ARRY-382, cFMS inhibitor; oral” NCT01316822 ↗ |
| Modality | Small molecule | — CHEMBL3644252 ↗ |
| Route | Oral | “ARRY-382, cFMS inhibitor; oral” NCT01316822 ↗ |
| Target | CSF1R | “ARRY-382 is an inhibitor of CSF1R (colony-stimulating factor-1 receptor).” NCT02880371 ↗ |